Search Videos and More

Showing 421 - 432 of 552 results

Previous| 1... 35 | 36 | 37 ...46 |Next


Study of Fully Vaccinated Patients with Cancer who had Breakthrough COVID-19 Shows 13% Mortality Rate News

Study of Fully Vaccinated Patients with Cancer who had Breakthrough COVID-19 Shows 13% Mortality Rate

The first study to evaluate the clinical characteristics and outcomes of fully vaccinated patients with cancer who had breakthrough COVID-19 infections indicates they remained at high risk for hospitalization and death.
COVID-19 and Cancer: Breakthrough Infections Video

COVID-19 and Cancer: Breakthrough Infections

New study: Fully vaccinated patients with cancer who had breakthrough COVID-19 infections remained at high risk for hospitalization and death. Dana-Farber's Toni Choueiri, MD, highlights the research.
Blood Cancer Research: Clinical trial helps younger patient Video

Blood Cancer Research: Clinical trial helps younger patient

Dr. Matthew Davids presented a study that demonstrated the ibrutinib+FCR drug combination keeps chronic lymphocytic leukemia in young patients in remission for several years.
COVID-19 vaccine and blood cancer Video

COVID-19 vaccine and blood cancer

Dr. Nikhil Munshi and colleagues reported a study demonstrating that COVID-19 vaccination offers less protection for multiple myeloma patients, reinforcing the need for these patients to use additional precautions.
Blood Cancer: Higher rates of precursor in high-risk individuals Video

Blood Cancer: Higher rates of precursor in high-risk individuals

Dr. Irene Ghobrial and Dr. Habib El-Khoury shared the first results from the Promise study, which screens individuals at high risk for multiple myeloma.
FDA Approval Offers Hope For Prevention of Acute Graft-Versus-Host Disease News

FDA Approval Offers Hope For Prevention of Acute Graft-Versus-Host Disease

Based on a clinical trial led by Leslie S. Kean, MD, PhD, of Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, the FDA has approved abatacept for the prevention of GVHD. This approval will allow many more patients to safely and effectively undergo stem cell transplants, particularly patients of diverse ethnicities who have more difficulty finding appropriately matched donors.
Drug Combination Found to Keep Chronic Lymphocytic Leukemia in Young Patients in Remission for Several Years News

Drug Combination Found to Keep Chronic Lymphocytic Leukemia in Young Patients in Remission for Several Years

A new study by Dana-Farber Cancer Institute researchers suggests that a 2.5-year regimen involving ibrutinib and chemoimmunotherapy can provide deep, and lasting remissions for patients with chronic lymphocytic leukemia (CLL).
Molecular Analysis Advances Risk Profiling and Assessment of Immunotherapy Response in Smoldering Myeloma News

Molecular Analysis Advances Risk Profiling and Assessment of Immunotherapy Response in Smoldering Myeloma

Molecular and genetic research by scientists at Dana-Farber Cancer Institute has advanced the categorization of different risk groups in patients with smoldering myeloma, a premalignant condition that can – but doesn’t always – progress to the blood cancer, multiple myeloma.
American Society of Hematology (ASH) Annual Meeting News

American Society of Hematology (ASH) Annual Meeting

As leaders in blood and blood cancer research, physicians and scientists from Dana-Farber Cancer Institute shared advances and insights at the 63rd Annual Meeting of the American Society of Hematology (ASH) on December 11–14, 2021 in Atlanta, Georgia
New Study Reveals Elevated Rates of Blood Cancer Precursor Condition in Groups at High Risk for Multiple Myeloma News

New Study Reveals Elevated Rates of Blood Cancer Precursor Condition in Groups at High Risk for Multiple Myeloma

The first results from the largest screening study yet conducted in the United States of individuals at above-average risk for the blood cancer multiple myeloma have revealed higher rates of a myeloma precursor condition in older adults who are Black or who have a close family member with a current or past blood cancer.
Study Identifies Factors in Tumors’ Response to Natural Killer Cells News

Study Identifies Factors in Tumors’ Response to Natural Killer Cells

The immune cells known as natural killer (NK) cells are part of the body’s first line of defense against cancer. Many efforts are underway to harness NK cells as a form of cancer immunotherapy, but a critical question in the field remains: Why do some tumors tend to be sensitive to NK cells’ attacks while others are more resistant?
Adjuvant Palbociclib in HR+/HER2 Early Breast Cancer - Final results from PALLAS Trial Video

Adjuvant Palbociclib in HR+/HER2 Early Breast Cancer - Final results from PALLAS Trial

Dana-Farber's Erica Mayer, MD, MPH discusses the final analysis of the International Phase 3 PALLAS clinical trial presented at the 2021 San Antonio Breast Cancer Symposium.

Showing 421 - 432 of 552 results

Previous| 1... 35 | 36 | 37 ...46 |Next